G1 Therapeutics, Inc. (NASDAQ:GTHX) reported Q2 EPS of ($0.92), $0.10 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $10.57 million versus the consensus estimate of $9.09 million.
G1 Therapeutics, Inc. (NASDAQ:GTHX) reported Q2 EPS of ($0.92), $0.10 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $10.57 million versus the consensus estimate of $9.09 million.